UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance

PharmacoEconomics, 2002, Vol.20 (8), p.513-528

2002

Volltextzugriff (PDF)

Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection

American journal of health-system pharmacy, 2006-04, Vol.63 (8), p.750-755

2006

Volltextzugriff (PDF)

The Current State of Multidrug-Resistant Gram-Negative Bacilli in North America : Insights from the Society of Infectious Diseases Pharmacists

Pharmacotherapy, 2008-02, Vol.28 (2), p.235-249

2008

Volltextzugriff (PDF)

Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem

Journal of clinical pharmacology, 2003-10, Vol.43 (10), p.1116-1123

2003

Volltextzugriff (PDF)

Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa , and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints

Infection and drug resistance, 2018-01, Vol.11, p.783-790

2018

Volltextzugriff (PDF)

Optimizing Pharmacodynamic Target Attainment Using the MYSTIC Antibiogram: Data Collected in North America in 2002

Antimicrobial Agents and Chemotherapy, 2004-07, Vol.48 (7), p.2464-2470

2004

Volltextzugriff (PDF)

Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection

Journal of antimicrobial chemotherapy, 2005-08, Vol.56 (2), p.388-395

2005

Volltextzugriff (PDF)

Optimising dosing strategies of antibacterials utilising pharmacodynamic principles : Impact on the development of resistance

Drugs (New York, N.Y.), 2006, Vol.66 (1), p.1-14

2006

Volltextzugriff (PDF)

Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem

Clinical therapeutics, 2004-08, Vol.26 (8), p.1187-1198

2004

Volltextzugriff (PDF)

The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe

Journal of antimicrobial chemotherapy, 2005-01, Vol.55 (1), p.71-77

2005

Volltextzugriff (PDF)

Clinical Efficacy and Pharmacoeconomics of a Continuous-Infusion Piperacillin-Tazobactam Program in a Large Community Teaching Hospital

Pharmacotherapy, 2002-04, Vol.22 (4), p.471-483

2002

Volltextzugriff (PDF)

Resource Utilization of Adults Admitted to a Large Urban Hospital With Community-Acquired Pneumonia Caused by Streptococcus pneumoniae

Chest, 2006-09, Vol.130 (3), p.807-814

2006

Volltextzugriff (PDF)

Making the most of surveillance studies: summary of the OPTAMA Program

Diagnostic microbiology and infectious disease, 2005-12, Vol.53 (4), p.281-287

2005

Volltextzugriff (PDF)

Population Pharmacokinetics and Pharmacodynamics of Meropenem in Pediatric Patients

Journal of clinical pharmacology, 2006-01, Vol.46 (1), p.69-75

2006

Volltextzugriff (PDF)

Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis

Clinical therapeutics, 2004-04, Vol.26 (4), p.493-501

2004

Volltextzugriff (PDF)

Cefditoren pivoxil: A novel broad-spectrum oral cephalosporin

Formulary (Cleveland, Ohio), 2001-04, Vol.36 (4), p.265

2001

Volltextzugriff (PDF)

Empiric Treatment of Multidrug‐Resistant Burkholderia cepacia Lung Exacerbation in a Patient with Cystic Fibrosis: Application of Pharmacodynamic Concepts to Meropenem Therapy

Pharmacotherapy, 2004-11, Vol.24 (11), p.1641-1645

2004

Volltextzugriff (PDF)

Clinical implications of extended spectrum β-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness

The Journal of infection, 2005-10, Vol.51 (3), p.211-217

2005

Volltextzugriff (PDF)

Use of Monte Carlo simulation to assess the pharmacodynamics of β-lactams against pseudomonas aeruginosa infections in children: A report from the OPTAMA program

Clinical therapeutics, 2005-11, Vol.27 (11), p.1820-1830

2005

Volltextzugriff (PDF)

Simulation of Antibiotic Pharmacodynamic Exposure for the Empiric Treatment of Nosocomial Bloodstream Infections: A Report from the OPTAMA Program

Clinical therapeutics, 2005-07, Vol.27 (7), p.1032-1042

2005

Volltextzugriff (PDF)

Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002

Diagnostic microbiology and infectious disease, 2004-06, Vol.49 (2), p.109-116

2004

Volltextzugriff (PDF)

Comparison of Pharmacodynamic Target Attainment Between Healthy Subjects and Patients for Ceftazidime and Meropenem

Pharmacotherapy, 2005-07, Vol.25 (7), p.935-941

2005

Volltextzugriff (PDF)

Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts

American journal of health-system pharmacy, 2004-06, Vol.61 (12), p.1264-1270

2004

Volltextzugriff (PDF)

Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral

American journal of health-system pharmacy, 2002-11, Vol.59 (22), p.2209-2215

2002

Volltextzugriff (PDF)

Pharmacodynamics of Meropenem and Imipenem Against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa

Pharmacotherapy, 2004-01, Vol.24 (1), p.8-15

2004

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(37)

Sprache

Englisch
(37)

Erscheinungsjahr

n.n

Thema

Science & Technology
(35)
Life Sciences & Biomedicine
(34)
Pharmacology & Pharmacy
(29)
Humans
(26)
Biological And Medical Sciences
(22)
Medical Sciences
(22)
Pharmacology. Drug Treatments
(18)
Microbial Sensitivity Tests
(14)
Pharmacodynamics
(14)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(13)
Infectious Diseases
(12)
Male
(12)
Meropenem
(12)
Monte Carlo Method
(12)
Anti-Bacterial Agents - Pharmacology
(10)
Antibacterial Agents
(10)
Antibiotics
(10)
Female
(10)
Middle Aged
(9)
Pseudomonas Aeruginosa
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance

Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection

The Current State of Multidrug-Resistant Gram-Negative Bacilli in North America : Insights from the Society of Infectious Diseases Pharmacists

Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem

Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa , and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints

Optimizing Pharmacodynamic Target Attainment Using the MYSTIC Antibiogram: Data Collected in North America in 2002

Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection

Optimising dosing strategies of antibacterials utilising pharmacodynamic principles : Impact on the development of resistance

Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem

The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe

Clinical Efficacy and Pharmacoeconomics of a Continuous-Infusion Piperacillin-Tazobactam Program in a Large Community Teaching Hospital

Resource Utilization of Adults Admitted to a Large Urban Hospital With Community-Acquired Pneumonia Caused by Streptococcus pneumoniae

Making the most of surveillance studies: summary of the OPTAMA Program

Population Pharmacokinetics and Pharmacodynamics of Meropenem in Pediatric Patients

Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis

Cefditoren pivoxil: A novel broad-spectrum oral cephalosporin

Empiric Treatment of Multidrug‐Resistant Burkholderia cepacia Lung Exacerbation in a Patient with Cystic Fibrosis: Application of Pharmacodynamic Concepts to Meropenem Therapy

Clinical implications of extended spectrum β-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness

Use of Monte Carlo simulation to assess the pharmacodynamics of β-lactams against pseudomonas aeruginosa infections in children: A report from the OPTAMA program

Simulation of Antibiotic Pharmacodynamic Exposure for the Empiric Treatment of Nosocomial Bloodstream Infections: A Report from the OPTAMA Program

Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002

Comparison of Pharmacodynamic Target Attainment Between Healthy Subjects and Patients for Ceftazidime and Meropenem

Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts

Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral

Pharmacodynamics of Meropenem and Imipenem Against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa

Suchergebnisse filtern